Korro Bio (NASDAQ:KRRO) Major Shareholder Forest Baskett Buys 207,100 Shares of Stock

Korro Bio, Inc. (NASDAQ:KRRO) major shareholder Forest Baskett purchased 207,100 shares of the stock in a transaction that occurred on Tuesday, March 10th. The stock was bought at an average cost of $11.11 per share, for a total transaction of $2,300,881.00. Following the acquisition, the insider directly owned 1,297,893 shares in the company, valued at $14,419,591.23. This trade represents a 18.99% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Korro Bio Price Performance

Shares of NASDAQ:KRRO traded down $0.26 during trading on Thursday, hitting $11.50. 92,041 shares of the company were exchanged, compared to its average volume of 184,676. Korro Bio, Inc. has a 52-week low of $5.20 and a 52-week high of $55.89. The stock has a 50 day moving average of $10.90 and a 200 day moving average of $20.23. The company has a market cap of $108.33 million, a PE ratio of -1.22 and a beta of 2.98.

Korro Bio (NASDAQ:KRRO) last announced its quarterly earnings results on Thursday, March 12th. The company reported ($5.32) EPS for the quarter. Korro Bio had a negative net margin of 1,199.53% and a negative return on equity of 68.87%. The firm had revenue of $1.29 million during the quarter. Sell-side analysts forecast that Korro Bio, Inc. will post -9.52 EPS for the current fiscal year.

Key Korro Bio News

Here are the key news stories impacting Korro Bio this week:

• Positive Sentiment: Multiple major shareholders and investors materially bought stock on March 10 — including Anthony A. Florence Jr., Paul E. Walker, Mohamad Makhzoumi, Edward T. Mathers, Forest Baskett, Rick Yang, Scott D. Sandell and Enterprise Associates 17 New — each acquiring 207,100 shares at $11.11, increasing their individual stakes by ~18.99%. Insider and large‑holder purchases often signal confidence in company prospects. SEC Filing (example)
• Positive Sentiment: Company reported an oversubscribed $85 million private placement that management says extends the cash runway into H2 2028 — reduces near‑term financing risk and supports ongoing programs. The corporate update also cited nominations of development candidates (KRRO‑121 for hyperammonemia indications and an advanced GalNAc conjugate program for alpha‑1 antitrypsin deficiency), indicating R&D progress. GlobeNewswire Press Release
• Negative Sentiment: Quarterly results were weak: KRRO reported a Q4 EPS loss of $(5.32), far worse than the consensus loss of $(1.93), with only $1.29M in revenue and a deeply negative net margin and ROE. The magnitude of the miss raises execution and cost concerns and likely pressured the stock despite the financing and insider buying. Zacks Coverage of Q4 Results

Institutional Investors Weigh In On Korro Bio

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. raised its position in Korro Bio by 6,185.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 199,249 shares of the company’s stock valued at $9,542,000 after purchasing an additional 196,079 shares in the last quarter. Emerald Mutual Fund Advisers Trust bought a new position in shares of Korro Bio during the 3rd quarter worth approximately $2,821,000. PNC Financial Services Group Inc. acquired a new stake in shares of Korro Bio in the 3rd quarter worth $140,000. Wealth Forward LLC acquired a new stake in Korro Bio in the third quarter worth about $240,000. Finally, CWM LLC grew its position in Korro Bio by 391.4% during the 3rd quarter. CWM LLC now owns 2,693 shares of the company’s stock worth $129,000 after purchasing an additional 2,145 shares during the last quarter. Institutional investors own 13.18% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on KRRO shares. Piper Sandler lowered Korro Bio from an “overweight” rating to a “neutral” rating and set a $11.00 price objective on the stock. in a research report on Thursday, November 13th. JonesTrading downgraded Korro Bio from a “buy” rating to a “hold” rating in a research note on Friday, November 14th. Chardan Capital upgraded shares of Korro Bio from a “neutral” rating to a “buy” rating and set a $15.00 price objective for the company in a research note on Thursday, January 29th. Royal Bank Of Canada downgraded Korro Bio from an “outperform” rating to a “sector perform” rating in a report on Thursday, November 13th. Finally, Raymond James Financial set a $18.00 target price on shares of Korro Bio in a report on Wednesday, February 18th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $50.38.

Korro Bio Company Profile

Korro Bio, Inc is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company’s proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases.

The company’s pipeline features both engineered enzyme therapeutics and live biotherapeutics.